- Home
- PHAT vs FFC Comparison
PHAT vs FFC Comparison
Compare PHAT & FFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- FFC
- Stock Information
- Founded
- PHAT 2018
- FFC 1983
- Country
- PHAT United States
- FFC United States
- Employees
- PHAT N/A
- FFC N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- FFC Trusts Except Educational Religious and Charitable
- Sector
- PHAT Health Care
- FFC Finance
- Exchange
- PHAT Nasdaq
- FFC Nasdaq
- Market Cap
- PHAT 769.0M
- FFC 798.8M
- IPO Year
- PHAT 2019
- FFC N/A
- Fundamental
- Price
- PHAT $13.55
- FFC $16.81
- Analyst Decision
- PHAT Strong Buy
- FFC
- Analyst Count
- PHAT 5
- FFC 0
- Target Price
- PHAT $17.60
- FFC N/A
- AVG Volume (30 Days)
- PHAT 1.3M
- FFC 164.1K
- Earning Date
- PHAT 10-30-2025
- FFC 01-01-0001
- Dividend Yield
- PHAT N/A
- FFC 6.79%
- EPS Growth
- PHAT N/A
- FFC N/A
- EPS
- PHAT N/A
- FFC N/A
- Revenue
- PHAT $147,190,000.00
- FFC N/A
- Revenue This Year
- PHAT $213.65
- FFC N/A
- Revenue Next Year
- PHAT $91.41
- FFC N/A
- P/E Ratio
- PHAT N/A
- FFC N/A
- Revenue Growth
- PHAT 460.30
- FFC N/A
- 52 Week Low
- PHAT $2.21
- FFC $11.90
- 52 Week High
- PHAT $19.50
- FFC $14.96
- Technical
- Relative Strength Index (RSI)
- PHAT 58.66
- FFC 56.77
- Support Level
- PHAT $13.02
- FFC $16.52
- Resistance Level
- PHAT $16.08
- FFC $16.82
- Average True Range (ATR)
- PHAT 1.05
- FFC 0.15
- MACD
- PHAT -0.02
- FFC 0.01
- Stochastic Oscillator
- PHAT 44.88
- FFC 78.38
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.